These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31950004)

  • 1. Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost.
    Houda SM; Toshihiro U; Yuriko Y; Hiroyuki O; Reie M; Anna S; Masafumi M
    Diabetol Int; 2020 Jan; 11(1):49-56. PubMed ID: 31950004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
    BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
    Billings LK; Agner BFR; Altuntas Y; Grøn R; Halladin N; Klonoff DC; Tentolouris N; Jódar E
    J Diabetes Sci Technol; 2021 May; 15(3):636-645. PubMed ID: 32107930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
    Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
    Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
    Gough SC; Bode BW; Woo VC; Rodbard HW; Linjawi S; Zacho M; Reiter PD; Buse JB
    Diabetes Obes Metab; 2015 Oct; 17(10):965-73. PubMed ID: 25980900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
    Kuhadiya ND; Dhindsa S; Ghanim H; Mehta A; Makdissi A; Batra M; Sandhu S; Hejna J; Green K; Bellini N; Yang M; Chaudhuri A; Dandona P
    Diabetes Care; 2016 Jun; 39(6):1027-35. PubMed ID: 27208343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
    Wang W; Agner BFR; Luo B; Liu L; Liu M; Peng Y; Qu S; Stachlewska KA; Wang G; Yuan G; Zhang Q; Ning G
    J Diabetes; 2022 Jun; 14(6):401-413. PubMed ID: 35762390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.
    Pasquel FJ; Urrutia MA; Cardona S; Coronado KWZ; Albury B; Perez-Guzman MC; Galindo RJ; Chaudhuri A; Iacobellis G; Palacios J; Farias JM; Gomez P; Anzola I; Vellanki P; Fayfman M; Davis GM; Migdal AL; Peng L; Umpierrez GE
    Diabetes Obes Metab; 2021 Jun; 23(6):1351-1360. PubMed ID: 33591621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
    Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
    Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
    Meier JJ; Rosenstock J; Hincelin-Méry A; Roy-Duval C; Delfolie A; Coester HV; Menge BA; Forst T; Kapitza C
    Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
    Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
    Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
    Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
    Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
    J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
    Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
    Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.